United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350, usp powder for oral solution is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

cardinal health - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350, usp powder for oral solution is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

proficient rx lp - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350, nf powder for oral solution is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 1 g in 1 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350, nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

proficient rx lp - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg/dl) hypertriglyceridemia.             usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp.             laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consi

United States - English - NLM (National Library of Medicine)

a-s medication solutions - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -  usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -  limitations of use: -  the

Israel - English - Ministry of Health

teva israel ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 240 mg - dimethyl fumarate - dimethyl fumarate teva is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis

Israel - English - Ministry of Health

teva israel ltd - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimethyl fumarate - dimethyl fumarate teva is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis

United States - English - NLM (National Library of Medicine)

a-s medication solutions - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg/dl) hypertriglyceridemia.             usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp.             laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consi